Immuron Ltd — Regulatory Filings 2007

Jun 17, 2007

Company Announcement

Anadis Secures Standby Subscriptions Agreement

Monday 18 June 2007

Melbourne, Australia - Anadis Ltd. (ASX:ANX) research driven biotechnology company is pleased to announce it has signed a \$5,000,000 Standby Subscription Agreement with Fortrend Small Cap Investors Limited. Under the facility, there is a commitment for Fortrend Small Cap to provide up to \$5,000,000, drawn down at Anadis discretion, through the issue of new shares to Fortrend. Anadis determines when to use this facility and is not obligated to any minimum subscription amount.

Dr Zeil Rosenberg, CEO of Anadis Ltd stated "This agreement is an additional vote of confidence we are receiving from investors for our renewed vision. It is a credit to the company that Fortrend Securities, after detailed review, made the decision to offer us this financing facility."

This facility will provide Anadis with additional access to capital, thereby allowing us to move forward with our innovative business strategy, to focus on expanding our R&D program and leveraging our intellectual property and know-how to become the leading developer and provider of polyclonal antibodies worldwide.

We are now even more prepared to leverage our capabilities and become a significant player in this industry, by partnering with corporate, government and academic partners. We plan to create significant value by synergistically combining royalty, product and custom solutions revenue, all based on our intellectual property portfolio and this Standby Subscription Agreement will further assist us in reaching this goal."

For further information contact:

Dr Zeil Rosenberg (US) - CEO Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Arie Nudel – Investor Relations Email: $\arceq n$ (a) anadis.com.au Tel: +61 3 9358 6388

Richard Allen – Media Email: richard@oxygenpr.com.au Tel: +61 3 9915 6341

About Anadis Limited

Anadis, Ltd. (ASX: ANX) is a research-driven biotechnology company focused on antibody-based therapeutic and preventive products. Anadis' proprietary rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases. The all-natural platform, and its regulatory classification as food rather than as a biological or drug, allows for a significantly shorter time frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability when compared with typical antibodybased solutions. The company is addressing existing market opportunities sized in excess of US \$30 Billion.

Leveraging a technology platform that has been carefully developed over a decade, the company expects to become the leading provider of proprietary polyclonal antibody-based solutions worldwide.

Pipeline

Target markets include both products and technologies the company plans to manufacture itself as well as out-license, respectively. The pipeline is expected to reach the market over the coming few years:

• Influenza Oral Solution providing Immediate-acting prevention and possible treatment of pandemic and seasonal influenza. The Anadis antibody platform allows for rapid modifications of the antibody profile in order to address new, emerging strains (e.g. avian influenza). Clinical studies expected to begin in '08.
• Bio-Defense- Diagnosis, containment and environmental decontamination. A Health and emergency response worker protection system against anthrax, plague and other bio-warfare agents with expansion potential to more routine bio-hazards including infectious agents, toxins and chemicals. The project received an award from The Australian Defense Department Science and Technology Office (DSTO).
• Nosocomial infections -Oral solutions for the prevention and treatment for top priority hospital and community acquired nosocomial infections. The company plans to conduct clinical studies for Clostridium difficile (c. Diff) in 2007-8.
• Enteric disease conditions including
• Travelers' Diarrhea (TD) (enterotoxigenic E. coli). This product, Travelan, is already being sold in Australia and has a global market.
• Inflammatory bowel disease and irritable bowel syndrome (IBD and IBS). A clinical study for use as an adjunct therapy in patients with Inflammatory Bowel Disease (IBD) started in late '06 and is being expanded to a multi-center study.
• Chemotherapy associated mucositis and Radiotherapy induced enteritis, diarrhea and other conditions that involve damage to the GI system. A clinical study begins in '07.

• BioShielding- Proprietary drug delivery technology to protect orally administered and fragile drugs, antibodies and vaccines from degradation in the digestion system. The technology platform also permits freeze-drying of proteins and vaccines, onto dry food, enabling use of dairy derived antibodies in food. The Company is in commercialization discussions with pharmaceutical and food manufacturing partners.

. Oncology Several major cancer research groups at major academic medical centers have indicated their interest to co-develop with Anadis the use of polyclonal antibodies in conjunction with their own proprietary oncology treatment approaches. Anadis expects to initiate animal and clinical studies during 2007-8.